NCT05440734 is a NA clinical trial of Melatonin in Insomnia, sponsored by Douglas Mental Health University Institute.

Who is sponsoring NCT05440734?

NCT05440734 is sponsored by Douglas Mental Health University Institute.

What drugs are being tested in NCT05440734?

Interventions in NCT05440734: Melatonin, Placebo.

Is NCT05440734 still recruiting?

NCT05440734 is currently terminated. Last updated 5 February 2025.

Last reviewed 2025-02-05 · How we verify

NCT05440734

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exogenous Melatonin in Postmenopausal Women with Insomnia

Terminated NA Last updated 5 February 2025

What this trial tests

NA trial testing Melatonin in Insomnia in 6 participants. Terminated before completion.

Timeline

17 June 2022

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Douglas Mental Health University Institute
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	6
Start date	17 June 2022
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across Canada

Drugs / interventions tested

Melatonin (MELATONIN) — full drug profile →
Placebo

Conditions studied

Insomnia — all drugs for Insomnia →

Sponsor

Douglas Mental Health University Institute

Who can join

Adults 45 to 65, female only, with Insomnia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to assess the effect of exogenous melatonin, 2 mg SR, 60 minutes before bedtime for 15 days, on the sleep and circadian rhythms of postmenopausal women with insomnia in a randomized crossover placebo-controlled study.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Melatonin: Facts, Extrapolations and Clinical Trials.
Boutin JA, Kennaway DJ, Jockers R. · · 2023 · cited 55× · PMID 37371523 · DOI 10.3390/biom13060943
Melatonin in Alzheimer's Disease: Literature Review and Therapeutic Trials.
Steinbach MJ, Denburg NL. · · 2024 · cited 13× · PMID 39422936 · DOI 10.3233/jad-230760
Exploration of the mechanism and therapy of ovarian aging by targeting cellular senescence.
Tang W, Wang K, Feng Y, Tsui KH, et al · · 2025 · cited 8× · PMID 40110109 · DOI 10.1093/lifemedi/lnaf004

Verify or expand the search:

Other trials of Melatonin

Trials testing the same drug.

NCT07221968 — Melatonin for the Treatment of DEE-SWAS · Phase 2 · not yet recruiting
NCT07503600 — The Effect of Adjunctive Melatonin With Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections · Phase 3 · not yet recruiting
NCT07375342 — Melatonin for Post Tonsillectomy Emergence Agitation in Pediatric · NA · enrolling by invitation
NCT07305350 — EFFICACY OF MELATONIN IN MANAGEMENT OF HYPOXIC ISCHEMIC ENCEPHALOPATHY (HIE) IN NEONATES · Phase 2 · active not recruiting
NCT07096635 — Oral Melatonin With Intra Articular Analgesia on Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction · NA · not yet recruiting

Other recruiting trials for Insomnia

Currently open trials in the same condition.

NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07270406 — Healthy Behaviors for Insomnia Prevention in People With HIV and Ongoing Pain · NA · recruiting
NCT07071324 — CF Wellness Program · NA · recruiting
NCT07417813 — A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders · recruiting
NCT06348082 — Project Women's Insomnia Sleep Health Equity Study (WISHES) · NA · recruiting

Other Douglas Mental Health University Institute trials

Trials by the same sponsor.

NCT07002996 — Spatial Memory Training and Cognitive Function · NA · recruiting
NCT06978465 — DIALOG: Understanding Disorganisation: A Language-focused Global Initiative in Psychosis · not yet recruiting
NCT06978452 — Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health Trajectories · recruiting
NCT06978894 — Predicting Psychotic Relapse Using Speech-Based Early Detection · recruiting
NCT06893393 — Virtual Travel Into Nature for Individuals With Lived Experience of Severe Mental Disorders · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05440734 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Douglas Mental Health University Institute
Last refreshed: 5 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05440734.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing